Market research
MIST Milestone Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 5.8571
- Dividend yield
- Not available
- Beta
- 0.98
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA59935V1076
- Market cap
- 129M
- P/E ratio
- Not available
- Analyst target
- 5.8571
- Dividend yield
- Not available
- Beta
- 0.98
About
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MIST discussion.
5 years, 4 months ago
Milestone Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 16.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Milestone Pharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.7% to $-50K since the same quarter in the previous year.
Finally, its free cash flow grew by 47.0% to $-9M since the same quarter in the previous year.
Based on the above factors, Milestone Pharmaceuticals Inc gets an overall score of 3/5.